WS
KALV

Wedbush Securities’s KalVista Pharmaceuticals KALV Stock Holding History

Wedbush Securities’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,550
Closed -$10K – 855
2016
Q3 		$10K Sell
1,550
-620
-29% -$4.67K ﹤0.01% 823
2016
Q2 		$20K Sell
2,170
-1,429
-40% -$16.6K ﹤0.01% 764
2016
Q1 		$32K Buy
3,599
+1,010
+39% +$18.1K 0.01% 715
2015
Q4 		$131K Buy
2,589
+996
+63% +$52.1K 0.02% 624
2015
Q3 		$80K Buy
+1,593
New +$136K 0.02% 643

Other funds holding KALV

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FQ
First Quadrant Glendale, California $18M AUM 24.2% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Wedbush Securities's KALV Position: Q4 2016 in Review

Wedbush Securities sold out of KalVista Pharmaceuticals (KALV) in Q4 2016, closing a stake of 1,550 shares — an estimated $10K sold.

Wedbush Securities first reported a position in KALV in Q3 2015 and held it in 5 quarters. The position peaked at $131K in Q4 2015. 20 funds tracked by Wall St. Rank hold KALV as of Q4 2016.

  • Wedbush Securities reported no remaining KalVista Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Wedbush Securities sold 1,550 KalVista Pharmaceuticals shares in Q4 2016, an estimated $10K.
  • Wedbush Securities first reported a position in KalVista Pharmaceuticals in Q3 2015 and held it in 5 quarters.
  • Wedbush Securities's KalVista Pharmaceuticals position peaked at $131K in Q4 2015.
  • 20 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2016.

Based on Wedbush Securities's 13F filing for Q4 2016, filed 25 Jan 2017.